Most people think dementia begins the moment memory problems start. But research shows the real story starts much earlier, sometimes decades earlier, inside the brain itself.

Scientists have identified specific proteins, called amyloid-beta and tau, that build up in the brain long before someone notices any change in memory or thinking. Understanding this timeline is changing how doctors approach early detection and opening doors to better planning and support for patients and families.

What Are Amyloid-Beta and Tau, and Why Do They Matter?

Amyloid-beta and tau are proteins that occur naturally in the brain. In a healthy brain, they’re broken down and cleared away without causing harm. But in people who go on to develop Alzheimer’s disease, these proteins begin to build up abnormally. Amyloid-beta clumps together to form plaques between brain cells, while tau forms tangles inside brain cells. Over time, this buildup damages the connections that allow the brain to function normally.

How Early Can These Brain Changes Be Detected?

According to research funded in part by the National Institutes of Health, brain scans (PET imaging) and spinal fluid tests can reveal these changes in the brain up to 20 years before symptoms of Alzheimer’s appear. A separate long-term study published in the New England Journal of Medicine followed nearly 650 people who developed Alzheimer’s and found measurable biomarker changes appearing on a similar timeline, roughly 20 years before diagnosis.
This means the disease process quietly begins in midlife for many people, long before any noticeable change in memory or daily function.

What Tools Are Used to Detect Early Brain Changes?

Researchers and doctors currently rely on a few key tools to identify these early changes, according to the Alzheimer’s Association:

• Brain imaging (PET scans): These scans can detect amyloid and tau buildup directly in the brain.
• Cerebrospinal fluid (CSF) testing: A sample of spinal fluid can reveal levels of amyloid and tau.
• Blood tests: Newer, less invasive blood tests are being developed to measure these biomarkers, making early detection more accessible than ever.

While some of these tools are already used in clinical and research settings, scientists continue to refine and validate them for wider use.

Why Early Detection Matters

Detecting dementia-related brain changes early doesn’t mean a diagnosis is guaranteed, but it does open the door to more options. According to the Alzheimer’s Association, the field is shifting from responding to symptoms after they appear to identifying risk and intervening much earlier, giving patients, families, and doctors more time to plan, monitor, and explore emerging treatment options.
For families, this shift also means more opportunity for meaningful conversations, informed decisions, and support, well before a crisis moment arrives.

You Don’t Have to Navigate This Alone

At Lower Cape Fear LifeCare, we understand that questions about memory, cognition, and long-term planning can feel overwhelming. Our team is here to help patients and families understand their options every step of the way, from early conversations to comprehensive dementia care. Contact us today to learn more.

Key Takeaways:

• Dementia-related brain changes can begin up to 20 years before symptoms appear.
• Amyloid-beta and tau are two key proteins involved in this process.
• Brain imaging, spinal fluid tests, and blood tests are current tools used to detect these changes early.
• Early detection is opening new doors for planning, monitoring, and future treatment options.

Sources:

1. National Institutes of Health, “New blood test method may predict Alzheimer’s disease,” https://www.nih.gov/news-events/nih-research-matters/new-blood-test-method-may-predict-alzheimers-disease
2. Alzheimer’s Association, “Earlier Diagnosis,” https://www.alz.org/alzheimers-dementia/research-and-progress/earlier-diagnosis
3. Jia J, et al., “Biomarker Changes during 20 Years Preceding Alzheimer’s Disease,” New England Journal of Medicine, https://www.nejm.org/doi/pdf/10.1056/NEJMoa2310168?listPDF=true